Indeed , percent reduction over PBO in baseline-adjusted focal seizure frequency/week ( primary efficacy analysis ) was 6.8 % ( p = 0.239 ) , 6.5 % ( p = 0.261 ) , and 11.7 % ( p = 0.037 ) for BRV 20 , 50 , and 100 mg/day , respectively .